Search research articles
Contact Us
Filters
Showing results (1-10 of 185) with videos related to
Page
of 19
Sort By:
The Lancet. Rheumatology
|
November 15, 2021
COVID-19 in systemic vasculitis and polymyalgia rheumatica: who is at risk of poor outcomes?
Sara Monti
Annals of the Rheumatic Diseases
|
May 17, 2020
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
September 23, 2020
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
May 2, 2020
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
May 2, 2020
Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
June 28, 2020
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
May 22, 2020
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
June 7, 2020
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
April 25, 2020
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
April 29, 2020
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta <i>et al</i> and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Page
of 19
Search research articles
Search
Showing results (1-10 of 185) with videos related to
Sort By:
Page
of 19
The Lancet. Rheumatology
|
November 15, 2021
COVID-19 in systemic vasculitis and polymyalgia rheumatica: who is at risk of poor outcomes?
Sara Monti
Annals of the Rheumatic Diseases
|
May 17, 2020
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
September 23, 2020
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
May 2, 2020
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
May 2, 2020
Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
June 28, 2020
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
May 22, 2020
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
June 7, 2020
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
April 25, 2020
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit
Sara Monti, Carlomaurizio Montecucco
Annals of the Rheumatic Diseases
|
April 29, 2020
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta <i>et al</i> and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi <i>et al</i>
Sara Monti, Carlomaurizio Montecucco
Page
of 19